<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of treatment of persistent pulmonary hypertension of the newborn (PPHN)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of treatment of persistent pulmonary hypertension of the newborn (PPHN)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Overview of treatment of persistent pulmonary hypertension of the newborn (PPHN)</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Key principles</td> </tr> <tr> <td>Identify and treat the underlying condition, if present (eg, sepsis, MAS, CDH, RDS) <p class="extra_spacing_top">Identify and correct metabolic derangements:</p> <ul class="decimal_heading"> <li>Metabolic acidosis should be avoided because it increases PVR; add acetate (2 to 3 mEq/kg per day) to IVF; avoid rapid infusion of sodium bicarbonate</li> <li>Treat hypoglycemia</li> <li>Treat hypocalcemia</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Severity assessment</td> </tr> <tr> <td><strong>Severity of hypoxemia:</strong> Calculate the OI: <span class="nowrap_whitespace">OI = [MAP × FiO2 ÷ PaO2] × 100</span> <ul class="decimal_heading"> <li>Mild hypoxemia: OI &lt;15</li> <li>Moderate hypoxemia: OI ≥15 and &lt;25</li> <li>Severe hypoxemia: OI ≥25 and &lt;40</li> <li>Very severe hypoxemia: OI ≥40</li> </ul> <p class="extra_spacing_top"><strong>Severity of PH</strong> based upon echocardiography:</p> <ul class="decimal_heading"> <li>Mild to moderate PPHN – Estimated RVp between one-half to three-quarters systemic BP</li> <li>Moderate to severe PPHN – Estimated RVp greater than three-quarters systemic BP but less than systemic BP</li> <li>Severe PPHN – Estimated RVp greater than systemic BP</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Ventilator management</td> </tr> <tr> <td>Most neonates with PPHN require intubation and MV: <ul class="decimal_heading"> <li>Begin with CMV using a patient-triggered volume-targeted mode</li> <li>Start with Tv of 4 to 6 mL/kg and PEEP of 5 to 7 cm H<sub>2</sub>O</li> <li>If gas exchange targets are not met with low Tv ventilation, the Tv setting can be liberalized</li> <li>If an FiO2 &gt;0.6 is required achieve the target SpO2, increase PEEP or transition to HFV</li> <li>Other reasons to transition to HFV: <ul> <li>Tvs of &gt;7 to 8 mL/kg are required to maintain gas exchange targets</li> <li>Peak pressures of 28 to 30 cm H<sub>2</sub>O are required to achieve adequate ventilation</li> <li>Neonate develops signs of ventilator-induced lung injury (eg, pneumothorax)</li> </ul> </li> <li>If OI is ≥25 despite optimizing MV and sedation, start iNO (see below)</li> </ul> <p class="extra_spacing_top"><strong>Gas exchange targets:</strong></p> <ul class="decimal_heading"> <li>Preductal SpO2: 90 to 95%</li> <li>Pre- and postductal SpO2 difference: &lt;3 to 5%</li> <li>PaCO2: 40 to 45 mmHg initially; can liberalize to 40 to 50 mmHg as neonate's ventilatory becomes more stable</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Sedation</td> </tr> <tr> <td>Agitation and dyssynchrony with the ventilator can increase PVR and worsen hypoxemia: <ul class="decimal_heading"> <li>Begin with opioid analgesia (morphine or fentanyl) alone or in combination with a benzodiazepine (midazolam)</li> <li>Reserve NMBAs (eg, vecuronium, pancuronium) for neonates with dyssynchronous breathing associated with persistent severe hypoxemia without another identified cause</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Hemodynamic support</td> </tr> <tr> <td>Most neonates with PPHN require hemodynamic support: <ul class="decimal_heading"> <li>Maintain adequate intravascular volume with IVF</li> <li>Provide inotropic and/or vasopressor support to maintain hemodynamic goals</li> <li>Dopamine, epinephrine, and milrinone are the most commonly used agents</li> </ul> <p class="extra_spacing_top"><strong>Hemodynamic goals:</strong></p> <ul class="decimal_heading"> <li>BP at upper limit of normal (eg, for term neonates, mean BP 45 to 55 mmHg; systolic BP 50 to 70 mmHg)</li> <li>Normal lactate level</li> <li>Improved right ventricular function and reduction in right-to-left shunting on serial echocardiography (if performed)</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Inhaled nitric oxide (iNO)</td> </tr> <tr> <td>Used in neonates with OI ≥25 despite optimizing MV and sedation: <ul class="decimal_heading"> <li>Dose: 20 ppm (do not use higher doses since this increases risk of toxicity without improving response)</li> <li>Weaning: <ul> <li>Start weaning once FiO2 is ≤0.6</li> <li>Wean by 5 ppm every 2 to 4 hours as tolerated until reaching a dose of 5 ppm</li> <li>Then wean by 1 ppm every 2 to 4 hours as tolerated until reaching a dose of 1 ppm</li> <li>If the neonate is stable on 1 ppm, discontinue iNO and monitor for rebound</li> <li>If the neonate has worsening hypoxemia and/or hemodynamic instability after stopping iNO, restart iNO at 5 ppm until the patient stabilizes, and subsequently wean more slowly</li> </ul> </li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Other interventions</td> </tr> <tr> <td><strong>Surfactant:</strong> Used in neonates with any of the following: <ul class="decimal_heading"> <li>PPHN associated with MAS or RDS</li> <li>PPHN associated with significant parenchymal lung disease, even if the etiology is not clearly MAS or RDS</li> </ul> <p class="extra_spacing"><strong>Transfusion:</strong> Threshold for RBC transfusion in neonates with severe PPHN is Hgb &lt;15 g/dL (HCT &lt;40%)</p> <strong>ECMO:</strong> Consider for neonates with OI ≥40 on maximal ventilatory support despite administration of iNO</td> </tr> <tr> <td class="subtitle1_single">Monitoring</td> </tr> <tr> <td>Appropriate monitoring includes: <ul class="decimal_heading"> <li>Pre- and post-ductal oxygen saturation (eg, with pulse oximetry probes placed on the right thumb and either great toe), monitored continuously</li> <li>Serial clinical assessments, including assessment of perfusion</li> <li>BP, monitored continuously with an indwelling arterial line</li> <li>Serial blood gases, monitored every 4 to 6 hours initially; then spaced out once the neonate's clinical status stabilizes</li> <li>Blood lactate levels</li> <li>Ventilator data (eg, peak inspiratory pressures and exhaled Tvs)</li> <li>Follow-up echocardiography, as needed</li> <li>Chest radiographs, as needed (eg, to assess lung volumes after initiating HFV or if there is an acute change in the neonate's clinical status)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes our suggested approach to managing PPHN. The guidance in this table applies to neonates with PPHN associated with severe lung disease. Occasionally, PPHN can occur without underlying lung disease (idiopathic PPHN), which we initially attempt to manage without invasive MV (eg, by administering iNO noninvasively with nasal cannula or CPAP). The guidance in this table reflects the practice at the author's institution. Practice is not standardized, and other centers may use a different approach. For further details, including the evidence supporting these interventions, refer to UpToDate's topics on PPHN.</div><div class="graphic_footnotes">PPHN: persistent pulmonary hypertension of the newborn; MAS: meconium aspiration syndrome; CHD: congenital diaphragmatic hernia; RDS: respiratory distress syndrome; PVR: pulmonary vascular resistance; IVF: intravenous fluid; FiO2: fraction of inspired oxygen; MAP: mean airway pressure; PaO2: arterial partial pressure of oxygen; RVp: right ventricular pressure; BP: blood pressure; MV: mechanical ventilation; CMV: conventional mechanical ventilation; Tv: tidal volume; PEEP: positive end-expiratory pressure; HFV: high frequency ventilation; iNO: inhaled nitric oxide; NMBA: neuromuscular blocking agents; SpO2: peripheral oxygen saturation; PaCO2: partial pressure of carbon dioxide; ppm: parts per million; RBC: red blood cell; Hgb: hemoglobin; HCT: hematocrit; ECMO: extracorporeal membrane oxygenation.</div><div id="graphicVersion">Graphic 140961 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
